Tazverik

Background

First-in-class, oral EZH2 inhibitor 

Approved applications

Tazverik was granted accelerated approval by the U.S. Food & Drug Administration (FDA) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Therapeutic Area

Treatment of epithelioid sarcoma and follicular lymphoma

Acquisition Date

Nov 2019

Marketer

Seller